You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

RIVASTIGMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rivastigmine, and when can generic versions of Rivastigmine launch?

Rivastigmine is a drug marketed by Alvogen, Amneal Pharms, Breckenridge, Mylan Technologies, Zydus Pharms, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs. and is included in fifteen NDAs.

The generic ingredient in RIVASTIGMINE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rivastigmine

A generic version of RIVASTIGMINE was approved as rivastigmine tartrate by SUN PHARM on October 22nd, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RIVASTIGMINE?
  • What are the global sales for RIVASTIGMINE?
  • What is Average Wholesale Price for RIVASTIGMINE?
Drug patent expirations by year for RIVASTIGMINE
Drug Prices for RIVASTIGMINE

See drug prices for RIVASTIGMINE

Recent Clinical Trials for RIVASTIGMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NeuroSense Therapeutics Ltd.Phase 2
Luye Pharma Group Ltd.Phase 1
St. Antonius HospitalPhase 4

See all RIVASTIGMINE clinical trials

Pharmacology for RIVASTIGMINE
Medical Subject Heading (MeSH) Categories for RIVASTIGMINE
Anatomical Therapeutic Chemical (ATC) Classes for RIVASTIGMINE
Paragraph IV (Patent) Challenges for RIVASTIGMINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EXELON Transdermal System Extended-release rivastigmine 13.3 mg/24 hr 022083 1 2013-01-22
EXELON Transdermal System Extended-release rivastigmine 4.6 mg/24 hr and 9.5 mg/24 hr 022083 1 2011-04-27

US Patents and Regulatory Information for RIVASTIGMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 203148-002 Aug 22, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 207797-001 Sep 28, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-002 Oct 22, 2007 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Orbion Pharms RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-002 Jun 10, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RIVASTIGMINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Actavis Group PTC ehf Rivastigmine Actavis rivastigmine EMEA/H/C/002036
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Authorised yes no no 2011-06-16
Krka, d.d., Novo mesto Nimvastid rivastigmine EMEA/H/C/001029
Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,
Authorised yes no no 2009-05-11
1 A Pharma GmbH Rivastigmine 1 A Pharma rivastigmine EMEA/H/C/001181
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Authorised no no no 2009-12-11
Novartis Europharm Limited Exelon rivastigmine EMEA/H/C/000169
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Authorised no no no 1998-05-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.